AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01757847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief MOVE-II control group intervention
Description: The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition to reinforcing the strategies taught during MOVE! and to provide support in implementing those strategies, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism.
Study NCT00154466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cardiac rehabilitation
Description: Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2); those in the nontraining group continued their usual lifestyle.
Study NCT01484366 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intramedullary nailing and plating
Description: Surgical intramedullary nailing of the ulna and plating of the radius
Study NCT01484366 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: plating
Description: Surgical plating of both bonforearm fractures
Study NCT04171076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation
Description: Theta burst stimulation at thoracic level (T5) over 2 minutes
Study NCT00976898 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Irradiation
Description: Given once a day, 5 days a week, for 3 weeks
Study NCT00523380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-21
Description: Administered i.v. in treatment cycles of 28 days.
Study NCT00523380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caelyx (pegylated liposomal doxorubicin)
Description: Administered i.v. in treatment cycles of 28 days.
Study NCT00555139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam
Description: Alprazolam capsules 0.25 mg are hard gelatine capsules containing 1 tablet of commercial alprazolam (Xanax 0.25).
Study NCT00555139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GW876008 placebo tablets will visually match the active GW876008 tablets. GSK561679 placebo tablets will visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that will visually match the active but containing only a filler.
Study NCT03657966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC/OvCa
Description: activated dendritic cells (DCVAC/OvCa) for immune maintenance after chemotherapy
Study NCT03657966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy
Description: either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa
Study NCT03691324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhalation technique training and discharge service
Description: Patient drug counselling one-to-one, focusing on inhalation drugs and technique
Study NCT01702181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPA-15406
Description: 0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days
Study NCT01702181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: 0.1% concentration of tacrolimus.
Study NCT01702181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01501084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: 10mcg sc (subcutaneous) injection once at one of the 2 MRI visits
Study NCT01501084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline .2cc subcutaneous injection
Description: sterile saline injection
Study NCT03419975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJO-002
Description: Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
Study NCT03419975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
Study NCT00256282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 30 mg/m2 IV over 6-10 min every 14 days
Study NCT00256282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 40mg/m2 IV over 1 hour every 14 days
Study NCT00256282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: 250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days
Study NCT01874990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high sodium diet
Description: The high-sodium diet was obtained by adding 6g of sodium chloride to the individual's regular diet
Study NCT01874990 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low-salt diet
Study NCT02923544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: YUMI manipulator
Study NCT04192162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mud therapy application
Description: Aplication the mud pack therapy from 20 minutes
Study NCT04192162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mud therapy application
Description: Aplication the mud pack therapy from 20 minutes
Study NCT04192162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sulfur water application
Description: Aplication the sulfur water in bath from 20 minutes
Study NCT04192162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sulfur water application
Description: Aplication the sulfur water in bath from 20 minutes
Study NCT04192162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hygienic water
Description: Exercise in hygienic water
Study NCT02935517 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGTC-402
Description: AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.
Study NCT04431687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D759, D150
Description: QD, PO
Study NCT01038817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duraphat
Description: After prophylactic cleaning of the mouth and teeth, application of fluoride varnish according to the manufacturer's recommendations (up to 0.75 ml per application)
Study NCT02788045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos.HIV
Description: Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
Study NCT02788045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Recombinant replication-deficient Ad26 vectored vaccine and consists of 4 Ad26 vectors, 2 containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5mL injection administered intramuscularly.
Study NCT02788045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C gp140
Description: Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
Study NCT03161717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural electrical stimulation (EES)
Description: Using loss of resistance technique and electrical stimulation
Study NCT03161717 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Loss of resistance (LOR)
Description: Using loss of resistance technique only
Study NCT00519194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epicor LP Cardiac Ablation System
Description: Surgical ablation of permanent AF during concomitant open chest and/or open heart surgery
Study NCT00519194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical ablation of permanent AF
Description: Concomitant AF ablation during mitral valve surgery
Study NCT02788045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 0.9 percent (%), 0.5 mL injection administered intramuscularly.
Study NCT03601819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Patients will receive continuous treatment until progressive disease, toxicity, or until any other condition for treatment discontinuation has been met.
Study NCT02177422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: telmisartan 80 mg once daily
Study NCT02177422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: 12.5 mg or 25 mg Hydrochlorothiazide in addition to telmisartan in case that the goal response (mean sitting diastolic blood pressure \< 90 mmHg) is not met after at least 4 weeks of treatment with telmisartan
Study NCT04511910 — intervention group
Intervention type: PROCEDURE
Intervention: Early Laparoscopic Cholecystectomy
Study NCT02277847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin(8mg/m2) and cytosine arabinoside
Description: IDA 8mg/M2 per day, D1-3. iv injection in 10 minutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
Study NCT02277847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin(10mg/m2), cytosine arabinoside
Description: IDA 10mg/M2 per day, D1-3. iv. injection in 10mimutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
Study NCT04231422 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Platelet-rich plasma
Description: 12mL of platelet-rich plasma injected into cavernosal bodies bilaterally
Study NCT03238781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was presented in identical containers, stored/packaged the same as AMG 301. All injections were administered within 30 minutes on treatment days.
Study NCT03238781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 301
Description: AMG 301 was packaged in 5 mL clear glass vials containing 1 mL of 70 mg/mL of AMG 301. All injections were administered within 30 minutes on treatment days.
Study NCT00624260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: semi-annual systematic PET-TDM
Description: semi-annual systematic PET-TDM
Study NCT00624260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PET-TDM for current indication
Description: PET-TDM for current indication (high isolated markers or before a metastasis curative resection)
Study NCT01953237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MedActive
Description: Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
Study NCT01953237 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone
Study NCT04167462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on Specified Days
Study NCT04167462 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on Specified days
Study NCT03171870 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: high resolution computed tomography
Description: high resolution computed tomography is an essential component of the diagnostic pathway in idiopathic pulmonary fibrosis. Unusual interstitial pneumonia is characterized on high resolution computed tomography by the presence of reticular opacities, often associated with traction bronchiectasis
Study NCT03938870 — intervention group
Intervention type: OTHER
Intervention: L-Leucine 13C6
Study NCT00581139 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Preparation Program (Child Life Specialist)
Description: This group will receive the standard preoperative visit to the hospital with Child Life intervention
Study NCT00581139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.5 mg/kg oral midazolam
Study NCT04657900 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational - no intervention given
Study NCT02606253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolvaptan
Description: Tolvaptan (Samsca) is a vasopressin 2 receptor antagonist that works in the collecting duct of the nephron to cause diuresis.
Study NCT02606253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorothiazide
Description: Chlorothiazide (Diuril) is an intravenous thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
Study NCT02606253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone
Description: Metolazone (Zaroxolyn) is an oral thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
Study NCT03650075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-S-2525
Description: The investigational product is MG-S-2525, which is an oral, small-molecule, anti-inflammatory agent. MG-S-2525 is being developed by Metagone Biotech Inc. and contains the new molecular entity HL0, an inhibitor of MAP3K19 which is up-regulated in disease pathobiology and in response to inflammatory stimuli in IPF.
Study NCT03650075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MG-S-2525
Description: The investigational product is MG-S-2525, which is an oral, small-molecule, anti-inflammatory agent. MG-S-2525 is being developed by Metagone Biotech Inc. and contains the new molecular entity HL0, an inhibitor of MAP3K19 which is up-regulated in disease pathobiology and in response to inflammatory stimuli in IPF.
Study NCT02649699 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3D MRI Scans
Description: Patients will receive additional MRI scans before commencing their radiation treatment, at 3-4 months, 6 months and 12 months post RT as well as at recurrence or suspected recurrence.
Study NCT03718000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daily self-weighing (DSW)
Description: DSW was conducted using digital WiFi scales during the holiday season. Participants received electronic graphic feedback of their weight fluctuations immediately after weight measurement.
Study NCT00559715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 1.25 mg intravitreally monthly/on demand
Study NCT00559715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5 mg intravitreally monthly/on demand
Study NCT01866592 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab
Description: Study participants will receive the FDA-approved dosing schedule for Adalimumab (Humira): an initial dose of 80mg followed by a 40mg maintenance dose every other week up to 52 weeks.
Study NCT02441283 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: ABT-493
Description: ABT-493 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
Study NCT02441283 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: ABT-530
Description: ABT-530 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
Study NCT04426032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Renal Doppler Ultrasound
Description: Measurement of Renal resistive index
Study NCT03279315 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iodized table salt, non-iodized table salt
Description: During the first 3 weeks, the diet was provided with non-iodized salt, while the diet with iodized salt was only offered in the last week.
Study NCT01543191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR118
Description: low dose and high dose for 3 doses, BID
Study NCT01543191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PUR118
Description: low dose and high dose for 3 doses, BID
Study NCT02806999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine; Insulin
Description: Participants will receive 500mg Berberine twice a day for 8 days; Meanwhile，participants will also continue to receive intensive insulin therapy.
Study NCT02806999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participants will continue to receive intensive insulin therapy; Meanwhile, Participants will also receive a placebo twice a day for 8 days.
Study NCT03110276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP001a
Description: 10 mg and 100 mg capsules. Number of capsules to be ingested will depend on the dose cohort. Administered orally once daily. Single dose (SAD) or 14 days treatment (MAD).
Study NCT03110276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, identical in appearance to the EYP001a 10 mg and 100 mg capsules.
Study NCT01995201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARD
Description: non-biological disease-modifying antirheumatic drugs at stable dose
Study NCT01995201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: stable dose
Study NCT01995201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg subcutaneously (SC) qw, Weeks 1-24
Study NCT01995201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg SC qw or q2w, Weeks 24-48
Study NCT01995201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg SC qw, Weeks 24-48
Study NCT01857518 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: -Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI
Description: * Visit V1: Diagnostic and clinical assessments~* Visit V2: psycho-behavioral assessment and neuroimaging~* Visit V3: Diagnostic and clinical assessments~* Visit V4: psycho-behavioral assessment and neuroimaging
Study NCT04557774 — intervention group
Intervention type: OTHER
Intervention: Cognitive function test
Description: Laboratory and imaging test~* Biochemical serum test: total bilirubin, alanine aminotransferase (ALT), haptoglobin, aspartate aminotransferase (AST), gamma glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), albumin, blood urea nitrogen, creatinine, α-fetoprotein (AFP), prothrombin time, blood glucose, triglycerides, and total cholesterol.~* Baseline evaluations: family and alcohol history, X-ray, electrocardiography, blood tests for electrolyte, liver function, and viral markers~Neuropsychological test~-Attention, Language, Visuospatial, Memory, Frontal/executive
Study NCT01449214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound-guided technique
Study NCT01449214 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmarking
Description: Landmark-guided technique
Study NCT00581139 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parental Presence during Induction of Anesthesia
Description: One parent will be present during induction of anesthesia of the child. The parent will be accompanied out of the OR by a nurse once the induction is completed. These parents will have completed a parent preparation program.
Study NCT00581139 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PPIA preparation program PLUS Midazolam premedication
Description: Subjects in this group will receive both interventions 2 and 3.
Study NCT01674491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: black soy peptide
Description: black soy peptide: 4.5g/day for 8 weeks
Study NCT01674491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: black soy peptide
Description: black soy peptide: 4.5g/day for 8 weeks
Study NCT04023461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVAC GOLD catheter ablation
Description: Isolation of pulmonary veins using PVAC GOLD catheter.